Adakitug by Bristol-Myers Squibb for Hormone-Sensitive Prostate Cancer: Likelihood of Approval

Adakitug is under clinical development by Bristol-Myers Squibb and currently in Phase II for Hormone-Sensitive Prostate Cancer.

Biopharma firm Zetagen raises $9.79m in Series B financing round

In preclinical research, Zetagen’s ZetaMAST showed potential to stop lesion growth. Credit: Zetagen. Clinical-stage biopharma firm Zetagen Therapeutics has raised $9.79m in a Series B

August 14, 2023

MemTrax continuous recognition test shows promise in early detection of Alzheimer’s disease

A new editorial paper was published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) Volume 15, Issue 12,

July 14, 2023

FDA Clears AI-Powered Non-Invasive Skin Cancer Detector

The FDA cleared an artificial-intelligence (AI)-powered device designed to non-invasively detect skin cancer in the primary care setting, the agency announced on Tuesday. Developer DermaSensor

January 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.